Your browser doesn't support javascript.
loading
Spine and Non-spine Bone Metastases - Current Controversies and Future Direction.
Challapalli, A; Aziz, S; Khoo, V; Kumar, A; Olson, R; Ashford, R U; Gabbar, O A; Rai, B; Bahl, A.
Affiliation
  • Challapalli A; Department of Clinical Oncology, Bristol Cancer Institute, Bristol, UK. Electronic address: amarnath.challapalli@uhbw.nhs.uk.
  • Aziz S; Department of Orthopaedics, University Hospitals of Leicester, Leicester, UK.
  • Khoo V; Department of Clinical Oncology, Royal Marsden Hospital, London, UK.
  • Kumar A; Department of Orthopaedics, Manchester University Hospitals, Manchester, UK.
  • Olson R; Department of Radiation Oncology, BC Cancer Centre for the North, British Columbia, Canada.
  • Ashford RU; Department of Orthopaedics, University Hospitals of Leicester, Leicester, UK; Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
  • Gabbar OA; Department of Orthopaedics, University Hospitals of Leicester, Leicester, UK.
  • Rai B; Department of Radiotherapy & Oncology, PGIMER, Chandigarh, India.
  • Bahl A; Department of Clinical Oncology, Bristol Cancer Institute, Bristol, UK.
Clin Oncol (R Coll Radiol) ; 32(11): 728-744, 2020 11.
Article in En | MEDLINE | ID: mdl-32747153
ABSTRACT
Bone is a common site of metastases in advanced cancers. The main symptom is pain, which increases morbidity and reduces quality of life. The treatment of bone metastases needs a multidisciplinary approach, with the main aim of relieving pain and improving quality of life. Apart from systemic anticancer therapy (hormonal therapy, chemotherapy or immunotherapy), there are several therapeutic options available to achieve palliation, including analgesics, surgery, local radiotherapy, bone-seeking radioisotopes and bone-modifying agents. Long-term use of non-steroidal analgesics and opiates is associated with significant side-effects, and tachyphylaxis. Radiotherapy is effective mainly in localised disease sites. Bone-targeting radionuclides are useful in patients with multiple metastatic lesions. Bone-modifying agents are beneficial in reducing skeletal-related events. This overview focuses on the role of surgery, including minimally invasive treatments, conventional radiotherapy in spinal and non-spinal bone metastases, bone-targeting radionuclides and bone-modifying agents in achieving palliation. We present the clinical data and their associated toxicity. Recent advances are also discussed.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spinal Neoplasms / Bone Neoplasms Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Oncol (R Coll Radiol) Journal subject: NEOPLASIAS Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spinal Neoplasms / Bone Neoplasms Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Oncol (R Coll Radiol) Journal subject: NEOPLASIAS Year: 2020 Document type: Article
...